Table 1 Clinicopathological characteristics of the study cohort in relation to ERG status
Characteristics | ERG negative | ERG positive | Total | P-value |
|---|---|---|---|---|
(n=492) | (n=547) | (n=1039) | ||
Age at RP, year | <0.0001* | |||
Median | 63.0 | 60.0 | 61.0 | |
s.d. | 7.2 | 7.5 | 7.5 | |
95% CI | 61.4–62.7 | 59.0–60.2 | 60.3–61.2 | |
Range | 35.0–82.0 | 41.0–78.0 | 35.0–82.0 | |
Age quartiles, year | <0.0001* | |||
1 (35–55) | 90 | 159 | 249 | |
2 (56–61) | 125 | 156 | 281 | |
3 (62–66) | 122 | 125 | 247 | |
4 (67–82) | 155 | 107 | 262 | |
BMI kg m − 2 | 0.407 | |||
Median | 26.0 | 26.0 | 26.0 | |
s.d. | 3.7 | 3.2 | 3.5 | |
95% CI | 26.5–27.3 | 26.2–26.9 | 26.5–30.0 | |
Range | 19.0–41.0 | 18–42 | 18–42 | |
PSA, indication to biopsy, ng ml −1 | 0.002* | |||
Median | 5.5 | 4.7 | 5.1 | |
s.d. | 5.5 | 5.1 | 5.3 | |
95% CI | 6.3–7.4 | 5.7–6.6 | 6.1–6.8 | |
Range | 1.2–57.9 | 1.35–54.7 | 1.2–57.9 | |
PSA ranges, ng ml −1 | 0.004* | |||
<4 | 109 | 165 | 274 | |
4–10 | 221 | 200 | 421 | |
>10 | 58 | 56 | 114 | |
Missing | 104 | 126 | 130 | |
fPSA%, indication to biopsy,% | 0.073 | |||
Mean | 13.9 | 13.0 | 13.3 | |
s.d. | 6.4 | 6.4 | 6.4 | |
95% CI | 14.0–15.4 | 13.1–14.4 | 13.7–14.7 | |
Range | 3.9–45.4 | 1.02–40.0 | 1.0–45.4 | |
PSA density, ng ml −2 | 0.409 | |||
Mean | 0.13 | 0.12 | 0.12 | |
s.d. | 0.21 | 0.14 | 0.18 | |
95% CI | 0.16–0.20 | 0.15–0.18 | 0.16–0.19 | |
Range | 0.03–2.31 | 0.02–1.05 | 0.02–2.31 | |
D’Amico score | 0.390* | |||
Low | 173 | 214 | 387 | |
Intermediate | 118 | 139 | 257 | |
High | 39 | 34 | 73 | |
Missing | 162 | 160 | 322 | |
PV, ml | 0.001* | |||
Mean | 40.0 | 35.0 | 39.0 | |
s.d. | 15.8 | 15.0 | 15.5 | |
95% CI | 41.2–44.5 | 41.2–44.5 | 39.9–42.2 | |
Range | 20.0–110.0 | 20.0–110.0 | 20.0–110.0 | |
TV, ml | 0.778 | |||
Mean | 1.30 | 1.32 | 1.30 | |
s.d. | 1.72 | 4.03 | 3.00 | |
95% CI | 1.57–2.05 | 1.83–3.09 | 1.79–2.41 | |
Range | 0.01–10.85 | 0.05–38.06 | 0.01–38.06 | |
Tumor volume % of PV (%TV), % | 0.404 | |||
Mean | 3.04 | 3.05 | 3.04 | |
s.d. | 3.13 | 7.51 | 5.89 | |
95% CI | 3.71–4.84 | 4.45–6.79 | 4.28–5.50 | |
Range | 0.02–21.69 | 0.12–56.80 | 0.02–56.80 | |
GS, n | 0.036* | |||
<7 | 167 (33.9) | 174 (31.8) | 341 (32.8) | |
7 | 253 (51.4) | 318 (58.1) | 571 (55.0) | |
>7 | 68 (13.8) | 52 (9.5) | 120 (11.5) | |
Missing | 4 (0.8) | 3 (0.5) | 7 (0.7) | |
pTNM, n | 0.697 | |||
pT2 | 356 (72.8) | 401 (73.3) | 757 (73.1) | |
pT3/4 | 132 (27.0) | 144 (26.3) | 276 (26.6) | |
Missing | 1 (0.2) | 2 (0.4) | 3 (0.3) | |
Nodal invasion, n | 0.032 | |||
Yes | 3 (0.6) | 5 (0.9) | 8 (0.8) | |
No | 216 (43.9) | 197 (36.0) | 413 (39.7) | |
Missing | 273 (55.5) | 345 (63.1) | 618 (59.5) | |
R, n | 0.454 | |||
Negative | 331 (67.3) | 371 (67.8) | 702 (67.6) | |
Positive | 126 (25.6) | 157 (28.7) | 283 (27.2) | |
Missing | 35 (7.1) | 19 (3.5) | 54 (5.2) | |
Biochemical recurrence | 0.994 | |||
Yes, n | 53 (10.8) | 60 (11.0) | 113 (10.9) | |
No, n | 378 (76.8) | 434 (79.3) | 812 (78.1) | |
Unknown, n | 61 (12.4) | 53 (9.7) | 114 (11.0) | |
Median time to recurrence, d | 667 | 998 | 832 | |
Range, d | 0–5071 | 0–3676 | 0–5071 | |
95% CI | 686–1294 | 913–1439 | 982–1286 | |
No biochemical recurrence | ||||
Median follow-up, d | 614 | 941 | 768 | |
Range | 27–6274 | 27–5657 | 27–6274 | |
95% CI | 685–1294 | 1248–1500 | 1184–1367 |
